Tenet Healthcare (NYSE: THC) COO receives 28,339 performance shares

Rhea-AI Filing Summary

Tenet Healthcare EVP and COO Lisa Y. Foo acquired 28,339 shares of common stock through a grant of performance-based restricted stock on February 13, 2026. The award was earned when the Human Resources Committee certified achievement of performance goals for the period from January 1, 2023 to December 31, 2025.

The shares were granted at no cash cost, with a reported price of $0.0000 per share, and increased her directly held common stock to 49,217 shares after the transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foo Lisa Y

(Last) (First) (Middle)

14201 DALLAS PARKWAY

(Street)

DALLAS TX 75254

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TENET HEALTHCARE CORP [ THC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A(1)		28,339	A	$0	49,217	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of performance-based restricted stock that was earned on the date the Human Resources Committee of the Company certified the achievement of the applicable performance targets based on the extent to which the applicable performance goals were attained for the performance period of January 1, 2023 to December 31, 2025.

	Chad J. Wiener, as Attorney-in-fact for Lisa Y. Foo	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tenet Healthcare (THC) report in this Form 4 for Lisa Y. Foo?

Tenet Healthcare reported that EVP and Chief Operating Officer Lisa Y. Foo received 28,339 shares of common stock through a grant of performance-based restricted stock, increasing her directly held stake to 49,217 shares after the transaction.

Was the Tenet Healthcare COO’s Form 4 transaction a stock purchase or an award?

The transaction was an award, not an open-market stock purchase. Lisa Y. Foo acquired 28,339 shares via a performance-based restricted stock grant, reported at a price of $0.0000 per share, reflecting equity compensation rather than a cash investment.

What performance period was used for Lisa Y. Foo’s restricted stock award at Tenet Healthcare (THC)?

The performance-based restricted stock award was earned based on goals measured over a performance period from January 1, 2023 to December 31, 2025. The Human Resources Committee certified the achievement of the applicable performance targets before the shares were granted.

How many Tenet Healthcare shares does Lisa Y. Foo hold after this Form 4 transaction?

After the reported grant, Lisa Y. Foo directly holds 49,217 shares of Tenet Healthcare common stock. This reflects the addition of 28,339 performance-based restricted shares earned upon certification of the company’s performance goals for the specified period.

Did Tenet Healthcare’s COO pay cash for the 28,339 awarded shares?

No cash was paid for the award. The 28,339 shares of common stock were granted as performance-based restricted stock, with the filing showing a transaction price per share of $0.0000, indicating equity compensation rather than a market purchase.